Rapport Therapeutics, Inc.
RAP-219
long-acting injectable
Countdown
178days
Phase 1 readout · ~ Jan 1, 2027 estimated
What's at stake
Phase 1 trial results for RAP-219 in long-acting injectable are due ~ Jan 1, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“RAP-219 long-acting injectable Phase 1 topline results (PK) 2027”